These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 17394072)

  • 1. High deferral rates and poorer treatment outcomes for HCV patients with psychiatric and substance use comorbidities.
    Evon DM; Verma A; Dougherty KA; Batey B; Russo M; Zacks S; Shrestha R; Fried MW
    Dig Dis Sci; 2007 Nov; 52(11):3251-8. PubMed ID: 17394072
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of hepatitis C treatment patterns in patients with and without psychiatric and/or substance use disorders.
    Chainuvati S; Khalid SK; Kancir S; Shea M; Edwards J; Sernyak M; Wongcharatrawee S; Garcia-Tsao G
    J Viral Hepat; 2006 Apr; 13(4):235-41. PubMed ID: 16611189
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Optimizing assessment and treatment for hepatitis C virus infection in illicit drug users: a novel model incorporating multidisciplinary care and peer support.
    Grebely J; Knight E; Genoway KA; Viljoen M; Khara M; Elliott D; Gallagher L; Storms M; Raffa JD; DeVlaming S; Duncan F; Conway B
    Eur J Gastroenterol Hepatol; 2010 Mar; 22(3):270-7. PubMed ID: 20425880
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Interferon-based hepatitis C treatment in patients with pre-existing severe mental illness and substance use disorders.
    Freedman K; Nathanson J
    Expert Rev Anti Infect Ther; 2009 Apr; 7(3):363-76. PubMed ID: 19344248
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Extending treatment for HCV infection to HIV-HCV coinfected individuals with psychiatric illness and drug dependence.
    Taylor LE; Schwartzapfel B; Allen S; Jacobs G; Mitty J
    Clin Infect Dis; 2003 Jun; 36(11):1501-2; author reply 1502-3. PubMed ID: 12766851
    [No Abstract]   [Full Text] [Related]  

  • 6. Surprisingly small effect of antiviral treatment in patients with hepatitis C.
    Falck-Ytter Y; Kale H; Mullen KD; Sarbah SA; Sorescu L; McCullough AJ
    Ann Intern Med; 2002 Feb; 136(4):288-92. PubMed ID: 11848726
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hepatitis C screening and treatment outcomes in patients with substance use/dependence disorders.
    Rifai MA; Moles JK; Lehman LP; Van der Linden BJ
    Psychosomatics; 2006; 47(2):112-21. PubMed ID: 16508022
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Psychiatric comorbidity does not predict interferon treatment completion rates in hepatitis C seropositive veterans.
    Dollarhide AW; Loh C; Leckband SG; Endow-Eyer R; Robinson S; Meyer JM
    J Clin Gastroenterol; 2007 Mar; 41(3):322-8. PubMed ID: 17426475
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Factors associated with HCV antiviral treatment uptake among participants of a community-based HCV programme for marginalized patients.
    Charlebois A; Lee L; Cooper E; Mason K; Powis J
    J Viral Hepat; 2012 Dec; 19(12):836-42. PubMed ID: 23121361
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Integrated Care Increases Treatment and Improves Outcomes of Patients With Chronic Hepatitis C Virus Infection and Psychiatric Illness or Substance Abuse.
    Ho SB; Bräu N; Cheung R; Liu L; Sanchez C; Sklar M; Phelps TE; Marcus SG; Wasil MM; Tisi A; Huynh L; Robinson SK; Gifford AL; Asch SM; Groessl EJ
    Clin Gastroenterol Hepatol; 2015 Nov; 13(11):2005-14.e1-3. PubMed ID: 25724704
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Multidisciplinary approach as a model for detection and monitoring of psychiatric morbidity in patients treated with interferon and ribavirin].
    Cabré Serres M; Rudi Sola N; Pontes García C; Vergara Gómez M; Parra Uribe I; Gorgas Torner MQ
    Farm Hosp; 2014 May; 38(3):162-8. PubMed ID: 24951901
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Widening the door: the evolution of hepatitis C treatment in patients with psychiatric disorders.
    Geppert CM; Arora S
    Hepatology; 2007 Oct; 46(4):957-9. PubMed ID: 17886300
    [No Abstract]   [Full Text] [Related]  

  • 13. Increasing antiviral treatment through integrated hepatitis C care: a randomized multicenter trial.
    Groessl EJ; Sklar M; Cheung RC; Bräu N; Ho SB
    Contemp Clin Trials; 2013 Jul; 35(2):97-107. PubMed ID: 23669414
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A novel program for treating patients with trimorbidity: hepatitis C, serious mental illness, and active substance use.
    Sockalingam S; Blank D; Banga CA; Mason K; Dodd Z; Powis J
    Eur J Gastroenterol Hepatol; 2013 Dec; 25(12):1377-84. PubMed ID: 23680911
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Management of mental health problems prior to and during treatment of hepatitis C virus infection in patients with drug addiction.
    Schaefer M; Sarkar R; Diez-Quevedo C
    Clin Infect Dis; 2013 Aug; 57 Suppl 2():S111-7. PubMed ID: 23884058
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Benefits of a preventive psychiatric accompaniment in patients Hepatitis C Virus seropositive (HCV): prospective study concerning 39 patients].
    Lang JP; Meyer N; Doffoel M
    Encephale; 2003; 29(4 Pt 1):362-5. PubMed ID: 14615706
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Reasons for HCV non-treatment in underserved African Americans: implications for treatment with new therapeutics.
    Schaeffer S; Khalili M
    Ann Hepatol; 2015; 14(2):234-42. PubMed ID: 25671833
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hepatitis C treatment for multimorbid patients with substance use disorder in a primary care-based integrated treatment centre: a retrospective analysis.
    Brunner N; Senn O; Rosemann T; Falcato L; Bruggmann P
    Eur J Gastroenterol Hepatol; 2013 Nov; 25(11):1300-7. PubMed ID: 23571610
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hepatitis C treatment in "difficult-to-treat" psychiatric patients with pegylated interferon-alpha and ribavirin: response and psychiatric side effects.
    Schaefer M; Hinzpeter A; Mohmand A; Janssen G; Pich M; Schwaiger M; Sarkar R; Friebe A; Heinz A; Kluschke M; Ziemer M; Gutsche J; Weich V; Halangk J; Berg T
    Hepatology; 2007 Oct; 46(4):991-8. PubMed ID: 17668880
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of sustained virological response to interferon therapy for hepatitis C to the hepatectomy for primary hepatocellular carcinoma.
    Tsujita E; Maeda T; Kayashima H; Harada N; Tsutsui S; Matsuda H; Kinjo N; Ikeda Y; Morita M; Ishida T
    Hepatogastroenterology; 2015; 62(137):157-63. PubMed ID: 25911888
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.